 | • レポートコード：GIR-2104Z10422 • 出版社/出版日：GlobalInfoResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、106ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療 |
| Single User | ￥504,600 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥756,900 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,009,200 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、過活動膀胱治療薬のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。過活動膀胱治療薬の種類別市場規模（抗コリン作用薬、ソリフェナシン、オキシブチニン、ダリフェナシン、フェソテロジン、トルテロジン、トロスピウム、その他）、用途別市場規模（特発性膀胱過活動、神経因性膀胱過活動）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・過活動膀胱治療薬の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Astellas Pharma, Inc. (Japan)、Pfizer, Inc. (US)、Teva Pharmaceutical Industries Limited (Israel)、Allergan, Plc (Ireland)、Medtronic plc (Ireland)、Mylan N.V. (US)、Endo International plc (Ireland)、Hisamitsu Pharmaceutical Co., Inc. (Japan)、Sanofi (France)、Apotex, Inc. (Canada)、Cogentix Medical, Inc. (US)、Aurobindo Pharma Limited (India) ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：抗コリン作用薬、ソリフェナシン、オキシブチニン、ダリフェナシン、フェソテロジン、トルテロジン、トロスピウム、その他 ・用途別分析2016年-2026年：特発性膀胱過活動、神経因性膀胱過活動 ・過活動膀胱治療薬の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・過活動膀胱治療薬のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・過活動膀胱治療薬のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・過活動膀胱治療薬の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・過活動膀胱治療薬の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Overactive Bladder Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Overactive Bladder Drug size is estimated to be USD xx million in 2025 from USD xx million in 2019, with a change XX% between 2019 and 2020. The global Overactive Bladder Drug market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Overactive Bladder Drug market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Anticholinergics
Solifenacin
Oxybutynin
Darifenacin
Fesoterodine
Tolterodine
Trospium
Others
Market segment by Application, can be divided into
Idiopathic Bladder Overactivity
Neurogenic Bladder Overactivity
Market segment by players, this report covers
Astellas Pharma, Inc. (Japan)
Pfizer, Inc. (US)
Teva Pharmaceutical Industries Limited (Israel)
Allergan, Plc (Ireland)
Medtronic plc (Ireland)
Mylan N.V. (US)
Endo International plc (Ireland)
Hisamitsu Pharmaceutical Co., Inc. (Japan)
Sanofi (France)
Apotex, Inc. (Canada)
Cogentix Medical, Inc. (US)
Aurobindo Pharma Limited (India)
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
1 Market Overview
1.1 Product Overview and Scope of Overactive Bladder Drug
1.2 Classification of Overactive Bladder Drug by Type
1.2.1 Overview: Global Overactive Bladder Drug Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Overactive Bladder Drug Revenue Market Share by Type in 2020
1.2.3 Anticholinergics
1.2.4 Solifenacin
1.2.5 Oxybutynin
1.2.6 Darifenacin
1.2.7 Fesoterodine
1.2.8 Tolterodine
1.2.9 Trospium
1.2.10 Others
1.3 Global Overactive Bladder Drug Market by Application
1.3.1 Overview: Global Overactive Bladder Drug Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Idiopathic Bladder Overactivity
1.3.3 Neurogenic Bladder Overactivity
1.4 Global Overactive Bladder Drug Market Size & Forecast
1.5 Global Overactive Bladder Drug Market Size and Forecast by Region
1.5.1 Global Overactive Bladder Drug Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Overactive Bladder Drug Market Size by Region, (2016-2021)
1.5.3 North America Overactive Bladder Drug Market Size and Prospect (2016-2026)
1.5.4 Europe Overactive Bladder Drug Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Overactive Bladder Drug Market Size and Prospect (2016-2026)
1.5.6 South America Overactive Bladder Drug Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Overactive Bladder Drug Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Overactive Bladder Drug Market Drivers
1.6.2 Overactive Bladder Drug Market Restraints
1.6.3 Overactive Bladder Drug Trends Analysis
2 Company Profiles
2.1 Astellas Pharma, Inc. (Japan)
2.1.1 Astellas Pharma, Inc. (Japan) Details
2.1.2 Astellas Pharma, Inc. (Japan) Major Business
2.1.3 Astellas Pharma, Inc. (Japan) Overactive Bladder Drug Product and Solutions
2.1.4 Astellas Pharma, Inc. (Japan) Overactive Bladder Drug Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Astellas Pharma, Inc. (Japan) Recent Developments and Future Plans
2.2 Pfizer, Inc. (US)
2.2.1 Pfizer, Inc. (US) Details
2.2.2 Pfizer, Inc. (US) Major Business
2.2.3 Pfizer, Inc. (US) Overactive Bladder Drug Product and Solutions
2.2.4 Pfizer, Inc. (US) Overactive Bladder Drug Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Pfizer, Inc. (US) Recent Developments and Future Plans
2.3 Teva Pharmaceutical Industries Limited (Israel)
2.3.1 Teva Pharmaceutical Industries Limited (Israel) Details
2.3.2 Teva Pharmaceutical Industries Limited (Israel) Major Business
2.3.3 Teva Pharmaceutical Industries Limited (Israel) Overactive Bladder Drug Product and Solutions
2.3.4 Teva Pharmaceutical Industries Limited (Israel) Overactive Bladder Drug Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Teva Pharmaceutical Industries Limited (Israel) Recent Developments and Future Plans
2.4 Allergan, Plc (Ireland)
2.4.1 Allergan, Plc (Ireland) Details
2.4.2 Allergan, Plc (Ireland) Major Business
2.4.3 Allergan, Plc (Ireland) Overactive Bladder Drug Product and Solutions
2.4.4 Allergan, Plc (Ireland) Overactive Bladder Drug Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Allergan, Plc (Ireland) Recent Developments and Future Plans
2.5 Medtronic plc (Ireland)
2.5.1 Medtronic plc (Ireland) Details
2.5.2 Medtronic plc (Ireland) Major Business
2.5.3 Medtronic plc (Ireland) Overactive Bladder Drug Product and Solutions
2.5.4 Medtronic plc (Ireland) Overactive Bladder Drug Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Medtronic plc (Ireland) Recent Developments and Future Plans
2.6 Mylan N.V. (US)
2.6.1 Mylan N.V. (US) Details
2.6.2 Mylan N.V. (US) Major Business
2.6.3 Mylan N.V. (US) Overactive Bladder Drug Product and Solutions
2.6.4 Mylan N.V. (US) Overactive Bladder Drug Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Mylan N.V. (US) Recent Developments and Future Plans
2.7 Endo International plc (Ireland)
2.7.1 Endo International plc (Ireland) Details
2.7.2 Endo International plc (Ireland) Major Business
2.7.3 Endo International plc (Ireland) Overactive Bladder Drug Product and Solutions
2.7.4 Endo International plc (Ireland) Overactive Bladder Drug Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Endo International plc (Ireland) Recent Developments and Future Plans
2.8 Hisamitsu Pharmaceutical Co., Inc. (Japan)
2.8.1 Hisamitsu Pharmaceutical Co., Inc. (Japan) Details
2.8.2 Hisamitsu Pharmaceutical Co., Inc. (Japan) Major Business
2.8.3 Hisamitsu Pharmaceutical Co., Inc. (Japan) Overactive Bladder Drug Product and Solutions
2.8.4 Hisamitsu Pharmaceutical Co., Inc. (Japan) Overactive Bladder Drug Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Hisamitsu Pharmaceutical Co., Inc. (Japan) Recent Developments and Future Plans
2.9 Sanofi (France)
2.9.1 Sanofi (France) Details
2.9.2 Sanofi (France) Major Business
2.9.3 Sanofi (France) Overactive Bladder Drug Product and Solutions
2.9.4 Sanofi (France) Overactive Bladder Drug Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Sanofi (France) Recent Developments and Future Plans
2.10 Apotex, Inc. (Canada)
2.10.1 Apotex, Inc. (Canada) Details
2.10.2 Apotex, Inc. (Canada) Major Business
2.10.3 Apotex, Inc. (Canada) Overactive Bladder Drug Product and Solutions
2.10.4 Apotex, Inc. (Canada) Overactive Bladder Drug Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Apotex, Inc. (Canada) Recent Developments and Future Plans
2.11 Cogentix Medical, Inc. (US)
2.11.1 Cogentix Medical, Inc. (US) Details
2.11.2 Cogentix Medical, Inc. (US) Major Business
2.11.3 Cogentix Medical, Inc. (US) Overactive Bladder Drug Product and Solutions
2.11.4 Cogentix Medical, Inc. (US) Overactive Bladder Drug Revenue, Gross Margin and Market Share (2019-2021)
2.11.5 Cogentix Medical, Inc. (US) Recent Developments and Future Plans
2.12 Aurobindo Pharma Limited (India)
2.12.1 Aurobindo Pharma Limited (India) Details
2.12.2 Aurobindo Pharma Limited (India) Major Business
2.12.3 Aurobindo Pharma Limited (India) Overactive Bladder Drug Product and Solutions
2.12.4 Aurobindo Pharma Limited (India) Overactive Bladder Drug Revenue, Gross Margin and Market Share (2019-2021)
2.12.5 Aurobindo Pharma Limited (India) Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Overactive Bladder Drug Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 5 Overactive Bladder Drug Players Market Share
3.2.2 Top 10 Overactive Bladder Drug Players Market Share
3.2.3 Market Competition Trend
3.3 Overactive Bladder Drug Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Overactive Bladder Drug Revenue and Market Share by Type (2016-2021)
4.2 Global Overactive Bladder Drug Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Overactive Bladder Drug Revenue Market Share by Application (2016-2021)
5.2 Overactive Bladder Drug Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Overactive Bladder Drug Revenue by Type (2016-2026)
6.2 North America Overactive Bladder Drug Revenue by Application (2016-2026)
6.3 North America Overactive Bladder Drug Market Size by Country
6.3.1 North America Overactive Bladder Drug Revenue by Country (2016-2026)
6.3.2 United States Overactive Bladder Drug Market Size and Forecast (2016-2026)
6.3.3 Canada Overactive Bladder Drug Market Size and Forecast (2016-2026)
6.3.4 Mexico Overactive Bladder Drug Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Overactive Bladder Drug Revenue by Type (2016-2026)
7.2 Europe Overactive Bladder Drug Revenue by Application (2016-2026)
7.3 Europe Overactive Bladder Drug Market Size by Country
7.3.1 Europe Overactive Bladder Drug Revenue by Country (2016-2026)
7.3.2 Germany Overactive Bladder Drug Market Size and Forecast (2016-2026)
7.3.3 France Overactive Bladder Drug Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Overactive Bladder Drug Market Size and Forecast (2016-2026)
7.3.5 Russia Overactive Bladder Drug Market Size and Forecast (2016-2026)
7.3.6 Italy Overactive Bladder Drug Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Overactive Bladder Drug Revenue by Type (2016-2026)
8.2 Asia-Pacific Overactive Bladder Drug Revenue by Application (2016-2026)
8.3 Asia-Pacific Overactive Bladder Drug Market Size by Region
8.3.1 Asia-Pacific Overactive Bladder Drug Revenue by Region (2016-2026)
8.3.2 China Overactive Bladder Drug Market Size and Forecast (2016-2026)
8.3.3 Japan Overactive Bladder Drug Market Size and Forecast (2016-2026)
8.3.4 South Korea Overactive Bladder Drug Market Size and Forecast (2016-2026)
8.3.5 India Overactive Bladder Drug Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Overactive Bladder Drug Market Size and Forecast (2016-2026)
8.3.7 Australia Overactive Bladder Drug Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Overactive Bladder Drug Revenue by Type (2016-2026)
9.2 South America Overactive Bladder Drug Revenue by Application (2016-2026)
9.3 South America Overactive Bladder Drug Market Size by Country
9.3.1 South America Overactive Bladder Drug Revenue by Country (2016-2026)
9.3.2 Brazil Overactive Bladder Drug Market Size and Forecast (2016-2026)
9.3.3 Argentina Overactive Bladder Drug Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Overactive Bladder Drug Revenue by Type (2016-2026)
10.2 Middle East & Africa Overactive Bladder Drug Revenue by Application (2016-2026)
10.3 Middle East & Africa Overactive Bladder Drug Market Size by Country
10.3.1 Middle East & Africa Overactive Bladder Drug Revenue by Country (2016-2026)
10.3.2 Turkey Overactive Bladder Drug Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Overactive Bladder Drug Market Size and Forecast (2016-2026)
10.3.4 UAE Overactive Bladder Drug Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global Overactive Bladder Drug Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Overactive Bladder Drug Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Overactive Bladder Drug Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Overactive Bladder Drug Revenue (USD Million) by Region (2016-2021)
Table 5. Global Overactive Bladder Drug Revenue Market Share by Region (2021-2026)
Table 6. Astellas Pharma, Inc. (Japan) Corporate Information, Head Office, and Major Competitors
Table 7. Astellas Pharma, Inc. (Japan) Major Business
Table 8. Astellas Pharma, Inc. (Japan) Overactive Bladder Drug Product and Solutions
Table 9. Astellas Pharma, Inc. (Japan) Overactive Bladder Drug Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Pfizer, Inc. (US) Corporate Information, Head Office, and Major Competitors
Table 11. Pfizer, Inc. (US) Major Business
Table 12. Pfizer, Inc. (US) Overactive Bladder Drug Product and Solutions
Table 13. Pfizer, Inc. (US) Overactive Bladder Drug Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Teva Pharmaceutical Industries Limited (Israel) Corporate Information, Head Office, and Major Competitors
Table 15. Teva Pharmaceutical Industries Limited (Israel) Major Business
Table 16. Teva Pharmaceutical Industries Limited (Israel) Overactive Bladder Drug Product and Solutions
Table 17. Teva Pharmaceutical Industries Limited (Israel) Overactive Bladder Drug Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Allergan, Plc (Ireland) Corporate Information, Head Office, and Major Competitors
Table 19. Allergan, Plc (Ireland) Major Business
Table 20. Allergan, Plc (Ireland) Overactive Bladder Drug Product and Solutions
Table 21. Allergan, Plc (Ireland) Overactive Bladder Drug Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Medtronic plc (Ireland) Corporate Information, Head Office, and Major Competitors
Table 23. Medtronic plc (Ireland) Major Business
Table 24. Medtronic plc (Ireland) Overactive Bladder Drug Product and Solutions
Table 25. Medtronic plc (Ireland) Overactive Bladder Drug Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Mylan N.V. (US) Corporate Information, Head Office, and Major Competitors
Table 27. Mylan N.V. (US) Major Business
Table 28. Mylan N.V. (US) Overactive Bladder Drug Product and Solutions
Table 29. Mylan N.V. (US) Overactive Bladder Drug Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Endo International plc (Ireland) Corporate Information, Head Office, and Major Competitors
Table 31. Endo International plc (Ireland) Major Business
Table 32. Endo International plc (Ireland) Overactive Bladder Drug Product and Solutions
Table 33. Endo International plc (Ireland) Overactive Bladder Drug Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Hisamitsu Pharmaceutical Co., Inc. (Japan) Corporate Information, Head Office, and Major Competitors
Table 35. Hisamitsu Pharmaceutical Co., Inc. (Japan) Major Business
Table 36. Hisamitsu Pharmaceutical Co., Inc. (Japan) Overactive Bladder Drug Product and Solutions
Table 37. Hisamitsu Pharmaceutical Co., Inc. (Japan) Overactive Bladder Drug Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Sanofi (France) Corporate Information, Head Office, and Major Competitors
Table 39. Sanofi (France) Major Business
Table 40. Sanofi (France) Overactive Bladder Drug Product and Solutions
Table 41. Sanofi (France) Overactive Bladder Drug Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Apotex, Inc. (Canada) Corporate Information, Head Office, and Major Competitors
Table 43. Apotex, Inc. (Canada) Major Business
Table 44. Apotex, Inc. (Canada) Overactive Bladder Drug Product and Solutions
Table 45. Apotex, Inc. (Canada) Overactive Bladder Drug Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Cogentix Medical, Inc. (US) Corporate Information, Head Office, and Major Competitors
Table 47. Cogentix Medical, Inc. (US) Major Business
Table 48. Cogentix Medical, Inc. (US) Overactive Bladder Drug Product and Solutions
Table 49. Cogentix Medical, Inc. (US) Overactive Bladder Drug Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 50. Aurobindo Pharma Limited (India) Corporate Information, Head Office, and Major Competitors
Table 51. Aurobindo Pharma Limited (India) Major Business
Table 52. Aurobindo Pharma Limited (India) Overactive Bladder Drug Product and Solutions
Table 53. Aurobindo Pharma Limited (India) Overactive Bladder Drug Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 54. Global Overactive Bladder Drug Revenue (USD Million) by Players (2019-2021)
Table 55. Global Overactive Bladder Drug Revenue Share by Players (2019-2021)
Table 56. Breakdown of Overactive Bladder Drug by Company Type (Tier 1, Tier 2 and Tier 3)
Table 57. Overactive Bladder Drug Players Head Office, Products and Services Provided
Table 58. Overactive Bladder Drug Mergers & Acquisitions in the Past Five Years
Table 59. Overactive Bladder Drug New Entrants and Expansion Plans
Table 60. Global Overactive Bladder Drug Revenue (USD Million) by Type (2016-2021)
Table 61. Global Overactive Bladder Drug Revenue Share by Type (2016-2021)
Table 62. Global Overactive Bladder Drug Revenue Forecast by Type (2021-2026)
Table 63. Global Overactive Bladder Drug Revenue by Application (2016-2021)
Table 64. Global Overactive Bladder Drug Revenue Forecast by Application (2021-2026)
Table 65. North America Overactive Bladder Drug Revenue by Type (2016-2021) & (USD Million)
Table 66. North America Overactive Bladder Drug Revenue by Type (2021-2026) & (USD Million)
Table 67. North America Overactive Bladder Drug Revenue by Application (2016-2021) & (USD Million)
Table 68. North America Overactive Bladder Drug Revenue by Application (2021-2026) & (USD Million)
Table 69. North America Overactive Bladder Drug Revenue by Country (2016-2021) & (USD Million)
Table 70. North America Overactive Bladder Drug Revenue by Country (2021-2026) & (USD Million)
Table 71. Europe Overactive Bladder Drug Revenue by Type (2016-2021) & (USD Million)
Table 72. Europe Overactive Bladder Drug Revenue by Type (2021-2026) & (USD Million)
Table 73. Europe Overactive Bladder Drug Revenue by Application (2016-2021) & (USD Million)
Table 74. Europe Overactive Bladder Drug Revenue by Application (2021-2026) & (USD Million)
Table 75. Europe Overactive Bladder Drug Revenue by Country (2016-2021) & (USD Million)
Table 76. Europe Overactive Bladder Drug Revenue by Country (2021-2026) & (USD Million)
Table 77. Asia-Pacific Overactive Bladder Drug Revenue by Type (2016-2021) & (USD Million)
Table 78. Asia-Pacific Overactive Bladder Drug Revenue by Type (2021-2026) & (USD Million)
Table 79. Asia-Pacific Overactive Bladder Drug Revenue by Application (2016-2021) & (USD Million)
Table 80. Asia-Pacific Overactive Bladder Drug Revenue by Application (2021-2026) & (USD Million)
Table 81. Asia-Pacific Overactive Bladder Drug Revenue by Region (2016-2021) & (USD Million)
Table 82. Asia-Pacific Overactive Bladder Drug Revenue by Region (2021-2026) & (USD Million)
Table 83. South America Overactive Bladder Drug Revenue by Type (2016-2021) & (USD Million)
Table 84. South America Overactive Bladder Drug Revenue by Type (2021-2026) & (USD Million)
Table 85. South America Overactive Bladder Drug Revenue by Application (2016-2021) & (USD Million)
Table 86. South America Overactive Bladder Drug Revenue by Application (2021-2026) & (USD Million)
Table 87. South America Overactive Bladder Drug Revenue by Country (2016-2021) & (USD Million)
Table 88. South America Overactive Bladder Drug Revenue by Country (2021-2026) & (USD Million)
Table 89. Middle East & Africa Overactive Bladder Drug Revenue by Type (2016-2021) & (USD Million)
Table 90. Middle East & Africa Overactive Bladder Drug Revenue by Type (2021-2026) & (USD Million)
Table 91. Middle East & Africa Overactive Bladder Drug Revenue by Application (2016-2021) & (USD Million)
Table 92. Middle East & Africa Overactive Bladder Drug Revenue by Application (2021-2026) & (USD Million)
Table 93. Middle East & Africa Overactive Bladder Drug Revenue by Country (2016-2021) & (USD Million)
Table 94. Middle East & Africa Overactive Bladder Drug Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Overactive Bladder Drug Picture
Figure 2. Global Overactive Bladder Drug Revenue Market Share by Type in 2020
Figure 3. Anticholinergics
Figure 4. Solifenacin
Figure 5. Oxybutynin
Figure 6. Darifenacin
Figure 7. Fesoterodine
Figure 8. Tolterodine
Figure 9. Trospium
Figure 10. Others
Figure 11. Overactive Bladder Drug Revenue Market Share by Application in 2020
Figure 12. Idiopathic Bladder Overactivity Picture
Figure 13. Neurogenic Bladder Overactivity Picture
Figure 14. Global Overactive Bladder Drug Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 15. Global Overactive Bladder Drug Revenue and Forecast (2016-2026) & (USD Million)
Figure 16. Global Overactive Bladder Drug Revenue Market Share by Region (2016-2026)
Figure 17. Global Overactive Bladder Drug Revenue Market Share by Region in 2020
Figure 18. North America Overactive Bladder Drug Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. Europe Overactive Bladder Drug Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. Asia-Pacific Overactive Bladder Drug Revenue (USD Million) and Growth Rate (2016-2026)
Figure 21. South America Overactive Bladder Drug Revenue (USD Million) and Growth Rate (2016-2026)
Figure 22. Overactive Bladder Drug Market Drivers
Figure 23. Overactive Bladder Drug Market Restraints
Figure 24. Overactive Bladder Drug Market Trends
Figure 25. Astellas Pharma, Inc. (Japan) Recent Developments and Future Plans
Figure 26. Pfizer, Inc. (US) Recent Developments and Future Plans
Figure 27. Teva Pharmaceutical Industries Limited (Israel) Recent Developments and Future Plans
Figure 28. Allergan, Plc (Ireland) Recent Developments and Future Plans
Figure 29. Medtronic plc (Ireland) Recent Developments and Future Plans
Figure 30. Mylan N.V. (US) Recent Developments and Future Plans
Figure 31. Endo International plc (Ireland) Recent Developments and Future Plans
Figure 32. Hisamitsu Pharmaceutical Co., Inc. (Japan) Recent Developments and Future Plans
Figure 33. Sanofi (France) Recent Developments and Future Plans
Figure 34. Apotex, Inc. (Canada) Recent Developments and Future Plans
Figure 35. Cogentix Medical, Inc. (US) Recent Developments and Future Plans
Figure 36. Aurobindo Pharma Limited (India) Recent Developments and Future Plans
Figure 38. Global Overactive Bladder Drug Revenue Share by Players in 2020
Figure 39. Overactive Bladder Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 40. Global Top 3 Players Overactive Bladder Drug Revenue Market Share in 2020
Figure 41. Global Top 10 Players Overactive Bladder Drug Revenue Market Share in 2020
Figure 42. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 43. Global Overactive Bladder Drug Revenue Share by Type in 2020
Figure 44. Global Overactive Bladder Drug Market Share Forecast by Type (2021-2026)
Figure 45. Global Overactive Bladder Drug Revenue Share by Application in 2020
Figure 46. Global Overactive Bladder Drug Market Share Forecast by Application (2021-2026)
Figure 47. North America Overactive Bladder Drug Sales Market Share by Type (2016-2026)
Figure 48. North America Overactive Bladder Drug Sales Market Share by Application (2016-2026)
Figure 49. North America Overactive Bladder Drug Revenue Market Share by Country (2016-2026)
Figure 50. United States Overactive Bladder Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. Canada Overactive Bladder Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. Mexico Overactive Bladder Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. Europe Overactive Bladder Drug Sales Market Share by Type (2016-2026)
Figure 54. Europe Overactive Bladder Drug Sales Market Share by Application (2016-2026)
Figure 55. Europe Overactive Bladder Drug Revenue Market Share by Country (2016-2026)
Figure 56. Germany Overactive Bladder Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. France Overactive Bladder Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. United Kingdom Overactive Bladder Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. Russia Overactive Bladder Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. Italy Overactive Bladder Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Asia-Pacific Overactive Bladder Drug Sales Market Share by Type (2016-2026)
Figure 62. Asia-Pacific Overactive Bladder Drug Sales Market Share by Application (2016-2026)
Figure 63. Asia-Pacific Overactive Bladder Drug Revenue Market Share by Region (2016-2026)
Figure 64. China Overactive Bladder Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Japan Overactive Bladder Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. South Korea Overactive Bladder Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 67. India Overactive Bladder Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. Southeast Asia Overactive Bladder Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. Australia Overactive Bladder Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. South America Overactive Bladder Drug Sales Market Share by Type (2016-2026)
Figure 71. South America Overactive Bladder Drug Sales Market Share by Application (2016-2026)
Figure 72. South America Overactive Bladder Drug Revenue Market Share by Country (2016-2026)
Figure 73. Brazil Overactive Bladder Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. Argentina Overactive Bladder Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. Middle East and Africa Overactive Bladder Drug Sales Market Share by Type (2016-2026)
Figure 76. Middle East and Africa Overactive Bladder Drug Sales Market Share by Application (2016-2026)
Figure 77. Middle East and Africa Overactive Bladder Drug Revenue Market Share by Country (2016-2026)
Figure 78. Turkey Overactive Bladder Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 79. Saudi Arabia Overactive Bladder Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 80. UAE Overactive Bladder Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 81. Methodology
Figure 82. Research Process and Data Source
世界の過活動膀胱治療薬市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Overactive Bladder Drug Market The global Overactive Bladder Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integrity, the re…- 世界の過活動膀胱治療薬市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Overactive Bladder Drug Market The global Overactive Bladder Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integrity, the re…
- 世界の過活動膀胱治療薬市場規模・現状・予測（2021年-2027年） Overactive bladder (OAB) is a bladder disorder that results in an abnormal urge to urinate, urinary frequency, and nocturia (voiding at night). Some patients may also experience urinary incontinence (involuntary loss of bladder control). North America is the largest consumption market of Overactive …
- 世界の膀胱がん治療市場規模・現状・予測（2021年-2027年） The bladder is an organ located in the lower abdominal region near the pelvic bones and acts as a reservoir of urine. A bladder cancer is characterized by the abnormal cell growth in the bladder, which impairs the proper functioning of urinary system. Majority of bladder cancer develops in the inner…
- 世界の膀胱がん治療・診断市場規模・現状・予測（2021年-2027年） The bladder is an organ located in the lower abdominal region near the pelvic bones and acts as a reservoir of urine. A bladder cancer is characterized by the abnormal cell growth in the bladder, which impairs the proper functioning of urinary system. Majority of bladder cancer develops in the inner…